Institution	Oklahoma State University - Center for Health Sciences
Meeting Date	Thursday, May 21 2026
Meeting Time	10:00AM
Meeting Type	Hybrid Meeting

IBC Members Present	Name	Role	Attendance
	Dr. Gerwald Koehler	Committee Chair	Absent
	Dr. I-Hsiu (George) Huang	Scientific Member	Present
	Dr. Sue Katz Amburn	Scientific Member	Present
	Dr. Crystal (Niki) Johnson	Scientific Member	Present
	William (BJ) Reddig	Lab representative	Present
	Dr. David Wallace	Animal Expert	Present
	>>>Dr. Wallace acted as chair for this meeting in Dr. Koehler's absence, and with Dr. Koehler's approval		
	Dr. Fang (Fiona) Liu	Non-affiliated member	Absent
	Jennifer Nangle	Non-affiliated Member	Absent
	Dr. Vikram Gujar	Alternate Member - Affiliated Scientist	Present, voted as scientific member
Quorum	Quorum is met. The IBC has six (6) voting members present, and four (4) voting members are required to conduct business.		

Others in Attendance	Name	Affiliation	Title
	Kadin Falkensten	Oklahoma State University - Center for Health Sciences	Research Compliance Coordinator, Biosafety Officer

Call to Order	The IBC Chair called this meeting to order at 10:04 am.
Conflicts of Interest	The IBC Chair asked all members present to identify any conflicts of interest with the materials that are to be reviewed. No colflicts of interest were identified.
Discussion of previous minutes	No discussion was held regarding the previous meeting's minutes. Dr. Johnson made the motion, and Dr. Gujar seconded. Dr. Huang was not present for the vote, and BR Reddig abstained.

Review and Approval of previous meeting minutes	Date of previous meeting	Motion	Votes; for/against/abstain
	Thursday, April 16 2026	Approve as written	4/0/1

Review of Prior Business	Business	Review and Discussion
	Report of pending/outstanding protocol(s)	At this time, there are no protocols pending review, and not protocols are outstanding from the previous meeting.

New IBC Registrations and Amendments for Review		
Review of IBC-00001216		
PI Name(s)	Dr. Malabika Maulik	
Registration Title/Number	Understanding the role of opioids in modulating glia-glia interactions	IBC-00001216

Project Overview	Using OliNeu mouse oligodendrocyte precursor and SIM9A mouse microglial cell lines, we want to investigate how pharmacological treatment and siRNA targeting of the HMGB1 will change the function of the oligodendrocytes and affect the downstream processes. We will further treat the SIM9A microglial cells with recombinant HMGB1 and conditioned medium from OliNeu cells treated pharmacological agents to identify the molecular markers that mediate neuroinflammation. Finally, we will co-culture OliNeu oligodendrocytes with SIM9A microglial cells to understand the interaction of these glial cells during pharmacological agent exposure. This study will use OliNeu mouse oligodendrocyte precursor cells, SIM9A mouse microglial cells; pLV[miR30]-{MBP_promoter}>EGFP :{mHmgb1[miR30-shRNA1]} (a lentivirus), and Mouse siRNA against HMGB1. The OliNeu and SIM9A cells are wild types, with no alterations made to them prior to their use in this study. The Mouse siRNA against HMGB1 gene (siRNA ID s67572, s67573 and s67574) will be purchased from ThermoFisher Scientific and will be used to knock down the HMGB1 gene in the SIM9a and OliNeu cell lines. The lentivirus targets the HMGB1 gene in rodent cells and will be used to confirm that the siRNA used has knocked down the HMGB1 gene. No Host/Vector systems are used in this study. No intentional modifications are made to any nucleic acid sequences as all will be used directly from the vendor, however there could be the potential for unanticipated modifications to these sequences due to molecular interactions within the cells. All materials used in this study will be destroyed completely as soon as possible to prevent any possible modifications from proliferating. This study will employ two primary experimental manipulations: tissue culture and work with recombinant and/or synthetic nucleic acids. The proposed biosafety level for this study is Biosafety Level 2.
NIH Guidelines Section	III-F-1, III-F-2
Risk Assessment and Discussion	Risk Assessment: Possibility of splashes, potential of sprays/aerosols from centrifugation Discussion: No discusion was held regarding the Rist Assessment.
Training	All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.

Additional Training	No additional training was identified as being needed by the IBC.		
Occupational Health Respresentative Review (if applicable)	No additional occupational health items were identified.		
Biosafety Level Assignment	Biosafety Level:	2	
	Additional Discussion or notes:	No additional discussion was held regarding the Biosafety level.	
IBC Vote	Motion:	Approve pending changes 1st: BJ Reddig	2nd: Dr. Johnson
	Votes, for/against/abstain/recused:		6/0/0/0
	Notes:	No additional comments or discussion was had regarding the vote.	

Review of IBC-00001258		
PI Name(s)	Dr. Malabika Maulik	
Registration Title/Number	Examining the effects of prenatal opioids and other opioid modulators on lifespan, healthspan, and epigenetic programming in models of C. elegans	IBC-00001258

Project Overview	This study advances understanding of how prenatal exposure to opioids and other modulators affects lifespan, healthspan and epigenetic programming by using Caenorhabditis elegans as a genetically tractable model. By examining long-term behavioral, physiological, and aging-related outcomes, the research provides mechanistic insight into how early-life opioid exposure programs long-term health trajectories. Findings from this work may help identify conserved molecular pathways involved in stress response, neurodevelopmental and epigenetic regulation, offering a foundation for future translational studies and therapeutic strategies aimed at mitigating the adverse effects of prenatal opioid exposure. The agents employed in this protocol are the nematode Caenorhabditis elegans, and very low amounts of Lipopolysaccharide (10ug total for the study). Lipopolysaccharide is a biological toxin, and appropriate care will be taken to ensure the safety of researchers and the wider community. No direct genetic manipulations are occurring during this study and not outside genetic material will be introduced to the C. elegans. No host/vector systems will be used in this study. The proposed biosafety level of this study is Biosafety Level 2.
NIH Guidelines Section	No NIH Guidelines sections were identified as being applicable for this protocol.
Risk Assessment and Discussion	Risk Assessment: Potential generation of splashes Discussion: No discussion was held regarding the risk assessment.
Training	All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.
Additional Training	No additional training was identified as being required by the IBC.
Occupational Health Respresentative Review (if applicable)	No additional occupational health concerns were noted.

Biosafety Level Assignment	Biosafety Level:	2	
	Additional Discussion or notes:	No additional discussion was held regarding the Biosafety level.	
IBC Vote	Motion:	Approve pending changes 1st: Dr. Katz Amburn	2nd: BJ Reddig
	Votes, for/against/abstain/recused:		6/0/0/0
	Notes:	No additional discussion was held regarding the IBC's vote.	

Review of IBC-00001260		
PI Name(s)	Dr. Nedra Wilson	
Registration Title/Number	Characterization of primary cilia on cell lines.	IBC-00001260
Project Overview	Primary cilia have recently been recognized as playing pivotal roles in the development of various neuropsychiatric and neurodevelopmental disorders. To learn more about the signaling pathways that regulate the assembly state of these organelles, we will use cell culture to characterize their morphology and proteins. We will examine the effect of various activators and inhibitors of signaling pathways on their morphology and protein composition. These studies will allow us to identify candidates for future studies to elucidate the role of specific proteins in the regulation of ciliary assembly and function as well as potential roles they might play in neuropsychiatric/developmental disorders. Four cell lines will be used in this study: A-172, SH-SY5Y, NIH3t3, and MDCK cells. All cell lines will not have genetic manipulations made on them and all will be of a wild-type characteristic. No host/vector systems will be employed in this study. No additional genetic materials will be employed outside of those normally found within the cell lines used. The primary experimental manipulations that will be employed will be tissue culture. The proposed biosafety level for this study is Biosafety Level 2.	
NIH Guidelines Section	No NIH Guidelines sections were noted as applying to this protocol.	
Risk Assessment and Discussion	Risk Assessment: Possible splashes; Spray/aerosols possible due to centrifugation, use of sharps	
	Discussion: No additional discussion was held regarding the biosafety level.	

Training	All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.		
Additional Training	No additional training was requested by the IBC.		
Occupational Health Respresentative Review (if applicable)	No additional occupational health concerns were noted.		
Biosafety Level Assignment	Biosafety Level:	2	
	Additional Discussion or notes:	No additional discussion was held regarding the Biosafety level	
IBC Vote	Motion:	Table until next meeting 1st:	2nd:
	Votes, for/against/abstain/recused:		0/0/0/0
	Notes:	The committee determined to table this protocol as a numbe of changes were noted as being required. This protocol will be reviewed at the next IBC meeting after the changes are made.	

Review of IBC-00001259		
PI Name(s)	Dr. Nedra Wilson	
Registration Title/Number	Characterization of a chronic subdural hematoma in a patient with Alzheimer disease.	IBC-00001259

Project Overview	This study will characterize a blood-filled bilateral sac identified in cadaveric tissue from an individual with a clinical diagnosis of Alzheimer disease. We will determine if this structure represents a previously undetected bilateral chronic subdural hematoma (cSDH) by determining the presence of neomembranes associated with cSDH. Although Alzheimer disease is the primary cause of death, the presence of bilateral cSDH raises important clinical and scientific questions regarding the potential contribution of chronic, subclinical, intracranial pathology to cognitive decline. Importantly, cSDH is known to cause clinical symptoms that overlap with Alzheimer disease and include cognitive impairment, executive dysfunction, and fluctuating mental status. The only agents collected during this study will be tissues from the brain of an embalmed, cadaveric individual. No tissue culture will be made from these collected tissues. Tissues will only undergo microscopic analysis, and no other agents will be employed during this study. No host/vector systems will be employed. No additional genetic materials will be used, and no genetic materials will be isolated from the collected tissues. The proposed biosafety level of this study will be Biosafety level 2.
NIH Guidelines Section	No NIH Guidelines were noted as applying to this protocol.
Risk Assessment and Discussion	Risk Assessment: Splashes possible, use of sharps. Discussion: No additional discussion was held regarding the risk assessment.
Training	All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.
Additional Training	No additional training was noted as being required for this protocol.
Occupational Health Respresentative Review (if applicable)	No additional occupational health concerns were noted.
Biosafety Level Assignment	Biosafety Level: 2

	Additional Discussion or notes:	No additional discussion was held regarding the biosafety level
IBC Vote	Motion:	Approve pending changes 1st: Dr. Johnson 2nd: BJ Reddig
	Votes, for/against/abstain/recused:	6/0/0/0
	Notes:	No additional discussion was held regarding the vote on this protocol.

New Business	Topic	Discussion
	No new business was discussed at this meeting	
Additional/Other Business	Notice of approval of IBC-00001257	Kadin Falkensten notified the committee that IBC-00001257 was approved in between the meetings. No action is required on the IBC's part, and no additional discussion was held.

Review of Incidents	No incidents were discussed at this meeting.
Inspections/Ongoing Oversight	No inspections or ongoing oversight were discussed at this meeting.
IBC Training	At this meeting, Kadin Falkensten informed the IBC about a new agent listing within Cayuse for C. elegans, and how to find it. Kadin noted that this is to allow the nematode to be listed within the protocols as a "agent" instead of just having is described wihing the text of the protocol.
Public Comments	No public comments were recorded at this meeting.
Adjournment	The IBC Chair moved to adjourn the meeting at 10:52 am. The next IBC meeting is scheduled for Thursday, June 18 2026.